Elicio receives supportive FDA feedback on ELI-002 Phase 3 registrational strategy

Elicio Therapeutics, Inc.

FDA aligned on Phase 3 study design: dose, schedule, patient population (KRAS-mutated pancreatic cancer), and DFS endpoint.
Phase 2 AMPLIFY-7P study fully enrolled; interim DFS analysis expected H1 2025.
Positive Phase 2 results could support rapid advancement into Phase 3 and potential BLA filing.
ELI-002 is an off-the-shelf monotherapy for mKRAS cancers patients post-chemotherapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.